Primobt
14 employees on LinkedIn ยท 1 known investors
A precision-medicine company that uses radiochemistry and molecular imaging to develop and manufacture radioisotope-based diagnostic and therapeutic drugs, focused on hard-to-treat cancers. It also pursues drug-development partnerships built on its radioisotope platform technology.
Also known as Primo ยท Primo Biotechnology Co., Ltd. ยท ๆฎ็้ป็ๆ
Founders & leadership
Investors ยท 1
Company profile
researched Aug 2026Primo Biotechnology Co., Ltd. (ๆฎ็้ป็ๆ, primobt.com) is a Taipei-headquartered precision-medicine company focused on the development and manufacturing of nuclear-medicine radiopharmaceuticals, positioning itself in radioligand theranostics (RLT) โ the pairing of non-invasive molecular imaging with targeted radiotherapy using the same molecular vector. Its stated approach combines a proprietary library of linker molecules with radiochemistry and molecular-imaging expertise to design diagnostic and therapeutic agents for cancer.
The company's commercial activities span four areas described on its site: radiopharmaceuticals for cancer diagnosis; supply of radionuclides including Terbium-161 and Lutetium-177; CRO/CDMO technical and consulting services supporting clinical trials and radiopharmaceutical R&D; and contracted transport of medical radioactive materials. Its lead diagnostic product in Taiwan is PB01, the local equivalent of Radelumin ([18F]PSMA-1007), a PSMA-targeting PET/CT tracer for prostate cancer licensed from Germany's ABX advanced biochemical compounds GmbH; Primo began supplying it for clinical use in Taiwan in June 2025. Additional pipeline candidates PB011 and PB012 are being advanced toward clinical trials in other cancer indications, and the company references a platform it calls Primo-X.
Primo sponsors clinical studies including a multicenter evaluation of [18F]FPSMA-1007 PET/CT in suspected prostate cancer (NCT05422105, started July 2023) and a Phase 1 study of PSMA PET for detecting liver metastases in colorectal cancer (NCT06935149, start date May 2025). A third-party database profile lists the company as founded in 2023 in Taiwan with 10-50 staff.
Business model
Primo develops and manufactures radiopharmaceuticals in internally certified GMP facilities and commercializes them in Taiwan, including in-licensed products such as Radelumin/PB01 distributed under authorization from ABX. It supplements product sales with radionuclide supply (Terbium-161, Lutetium-177), CRO/CDMO services for radiopharmaceutical development and clinical trials, and contracted transport of medical radioactive materials. The company also seeks drug-development partnerships that combine partners' therapeutic expertise with its radioisotope platform, and pursues out-licensing partners to expand pipeline products into global markets.
Revenue is derived from supplying and distributing radiopharmaceutical products for clinical use in Taiwan, radionuclide supply, and fee-based CRO/CDMO and radioactive-material logistics services. Management states that pursuing Taiwan's Category 2 new-drug registration pathway (e.g., new indications) rather than Category 1 new chemical entities lowers cost, time and risk and is expected to accelerate revenue generation.
Traction
Primo reported cumulative capital raised of more than NT$500 million as of July 2025, dual PIC/S GMP and GDP certification of its manufacturing facility, commercial supply of Radelumin ([18F]PSMA-1007) in Taiwan from June 2025, two registered company-sponsored clinical trials, dosing of a first patient in a colorectal cancer radiopharmaceutical program in January 2026, and a 2026 startup award at BIO Asia. It has stated plans to file for TPEx Emerging Stock Board registration and to pursue an IPO in 2026.
Latest developments
In 2026 the company reported the first patient enrolled in its colorectal cancer radiopharmaceutical program (January 2026), the first PSMA PET imaging procedure in the Hualien-Taitung region at Hualien Tzu Chi Hospital (January 2026), the recruitment of radiopharmaceutical specialist Dr. Peng Chi-Chun (July 2026), and an outstanding biotech startup award tied to its Primo-X platform announced around BIO Asia 2026. It also published or highlighted research on PSMA and non-PSMA PET tracers, radium-223 outcomes in metastatic castration-resistant prostate cancer, and cost-utility of 18F-FDG imaging.
โธFull profile โ market position, technology, go-to-market, geography, history, risks & controversies
Market position
Primo describes itself as a pioneering radiopharmaceutical developer in Taiwan and reports being the sponsor of the first multicenter clinical trial of 18F-PSMA-1007 in the country. It holds Taiwanese manufacturing and distribution rights for ABX's Radelumin, a product already approved in France, Germany, the Netherlands and other countries, and reported receiving a 2026 outstanding biotech startup award at BIO Asia 2026 for its Primo-X platform.
The company combines in-house GMP/GDP-certified radiopharmaceutical manufacturing with a proprietary linker-molecule library and theranostic design pairing imaging and therapy using the same targeting molecule. It also emphasizes a regulatory strategy using Taiwan's Category 2 new-drug pathway for new indications, which it says reduces development cost, time and risk relative to new chemical entities.
Technology
The company works in radiochemistry and molecular imaging, with a proprietary library of linker molecules used to construct radioligand diagnostic and therapeutic agents. Its diagnostic products use PET/CT imaging with fluorine-18-labelled PSMA-targeting tracers ([18F]PSMA-1007) to visualize prostate-specific membrane antigen expression, and it supplies therapeutic radionuclides Terbium-161 and Lutetium-177. Manufacturing is carried out at a radiopharmaceutical facility that received PIC/S GMP and GDP certifications in April 2025.
Go-to-market
The company markets directly to Taiwanese clinical sites, supported by in-licensing agreements with international radiopharmaceutical suppliers such as ABX, hospital collaborations (for example Hualien Tzu Chi Hospital's first PSMA PET imaging in eastern Taiwan), sponsored clinical trials that build local clinical evidence, and participation in professional and industry events such as TUA 2026 and BIO Asia 2026. It also states it pursues licensing partners to expand into global markets.
Hospitals and nuclear medicine and oncology departments in Taiwan that use PET/CT imaging and radioligand therapy for cancer patients โ particularly prostate and colorectal cancer โ as well as pharmaceutical and biotech partners seeking radionuclide supply, CDMO/CRO services or co-development on a radioisotope platform.
Geography
Headquartered in Taipei, Taiwan, with commercial operations and clinical activity across Taiwan including eastern Taiwan (Hualien Tzu Chi Hospital). International ties include a licensing and supply partnership with Germany-based ABX and knowledge exchange with Korean clinicians on PSMA PET practice.
History
A third-party company database records Primo Biotechnology Co., Ltd. as established in 2023 in Taiwan. It sponsored a multicenter [18F]PSMA-1007 PET/CT trial starting July 2023, formed its partnership with ABX in March 2025, obtained PIC/S GMP and GDP facility certifications in April 2025, began clinical supply of Radelumin in Taiwan in June 2025, and closed a NT$220 million Series A round announced on 2 July 2025 that brought cumulative capital raised above NT$500 million.
Risks & controversies
The company's stated 2026 IPO and TPEx Emerging Stock Board filing plans are forward-looking and unconfirmed in the material. Its lead marketed diagnostic depends on an in-licensing relationship with ABX, and its proprietary candidates PB011 and PB012 remain at clinical-trial planning or early clinical stages, with one sponsored trial listed as not yet recruiting.
Compiled by commissioned research from 8 cited public sources โ announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed โ not independently audited.
Timeline ยท 11
launches, deals, and filingsThe company announced the recruitment of radiopharmaceutical expert Dr. Peng (ๅฝญๅ้) to strengthen its radiodiagnostic and therapeutic drug development platform.
The company reported receiving a 2026 outstanding biotech startup award, associated with its Primo-X platform for cancer radiodiagnostics and therapy, announced around BIO Asia 2026.
Hualien Tzu Chi Hospital completed the first prostate-specific membrane antigen PET imaging procedure in the Hualien-Taitung region, reported by the company.
The company reported enrolling and dosing the first patient in a study of its radiopharmaceutical for precision diagnosis and treatment of colorectal cancer.
The company said it plans to launch an IPO in 2026 and to file for registration on Taiwan's TPEx Emerging Stock Board.
Primo announced completion of a NT$220 million Series A round, bringing total capital raised, including seed and early-stage investments, above NT$500 million.
After receiving authorization from ABX to act as manufacturing and distribution partner in Taiwan, Primo started supplying the prostate cancer diagnostic radiopharmaceutical Radelumin ([18F]PSMA-1007) for clinical use in Taiwan.
Primo is listed as sponsor of NCT06935149, a Phase 1 study evaluating PSMA PET for detecting liver metastatic lesions in colorectal cancer patients, with a start date of 1 May 2025.
The company's radiopharmaceutical manufacturing facility obtained dual international PIC/S GMP and GDP certifications, per the CEO's statement in the July 2025 funding announcement.
Primo formed a partnership with Germany-based ABX advanced biochemical compounds GmbH to prepare the introduction of PB01, the Taiwanese equivalent of the PSMA-targeting PET/CT diagnostic radiotracer Radelumin, to the Taiwanese prostate cancer market.
Primo is listed as sponsor/collaborator of NCT05422105, a multicenter evaluation of the diagnostic performance of [18F]FPSMA-1007 PET/CT in patients with suspected prostate cancer, described as the first multicenter clinical trial of 18F-PSMA-1007 in Taiwan.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
โธResearch sources ยท 8
primary sources listed
- Primobtprimobt.com ยท web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Primobt do?
- Taiwan-based radiopharmaceutical company developing and manufacturing radioligand diagnostics and therapies for cancer.
- Who founded Primobt?
- Primobt was founded by ้ป้ ็ค, ่่ๅ .
- Who are Primobt's investors?
- Primobt's investors include AVA Angels.